Share Price and Basic Stock Data
Last Updated: December 19, 2025, 3:34 pm
| PEG Ratio | -11.15 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Amrutanjan Health Care Ltd has carved a niche for itself in the pharmaceuticals sector, focusing on over-the-counter healthcare products. The company reported a market capitalization of ₹1,852 Cr and a share price of ₹640, reflecting a P/E ratio of 32.7. This valuation indicates that investors are paying a premium for future growth expectations, which is not uncommon in the healthcare sector. Over the past few quarters, the company’s revenue trajectory has shown fluctuations, with sales rising to ₹127.06 Cr in March 2024 before declining to ₹83.74 Cr in June 2024. The trailing twelve months (TTM) sales stood at ₹462 Cr, indicating a robust demand for its products despite the quarterly variations. This performance is particularly notable given the backdrop of increased health consciousness among consumers, which bodes well for the company’s future. However, the inconsistency in quarterly sales highlights the need for Amrutanjan to stabilize its revenue streams, especially in a competitive market.
Profitability and Efficiency Metrics
Profitability metrics for Amrutanjan depict a company that is navigating its operational challenges while maintaining a reasonable level of efficiency. The operating profit margin (OPM) fluctuated, peaking at 18.44% in December 2023 but falling to 4.24% in June 2024. This significant drop raises questions about cost management and pricing strategies during periods of lower sales. The net profit for the fiscal year 2025 was reported at ₹51 Cr, translating to an EPS of ₹17.58. The return on equity (ROE) stood at 16.5%, which is decent, suggesting that the company is generating a reasonable return for its shareholders. However, the return on capital employed (ROCE) of 22.4% indicates that while profitability remains intact, Amrutanjan must enhance its operational efficiency to improve margins further. The interest coverage ratio of 78.72x highlights a very low debt burden, providing a cushion against financial distress, yet the OPM volatility could be a concern for long-term investors.
Balance Sheet Strength and Financial Ratios
Amrutanjan’s balance sheet appears solid, characterized by minimal borrowings of just ₹2 Cr against reserves of ₹339 Cr. This low leverage reflects a prudent financial strategy that positions the company well to weather economic uncertainties. The current ratio stands comfortably at 3.46, indicating that the company has more than enough short-term assets to cover its liabilities. However, the price-to-book value (P/BV) ratio at 6.85x suggests that the stock may be overvalued in comparison to its book value, which could deter value-oriented investors. Moreover, the cash conversion cycle of -23 days illustrates efficient working capital management, allowing Amrutanjan to convert its investments into cash quickly. However, the rising inventory days and debtor days in recent periods could signal potential liquidity challenges if not addressed promptly. Overall, while the balance sheet shows strength, the high valuation metrics may raise caution among prospective investors.
Shareholding Pattern and Investor Confidence
The shareholding structure of Amrutanjan Health Care Ltd reveals a stable yet slightly declining trend in promoter holdings, which stood at 46.52%. This reduction might indicate a dilution of control, but it could also be a strategic move to attract institutional investment. The presence of foreign institutional investors (FIIs) has grown to 2.38%, while domestic institutional investors (DIIs) hold 12.90% of the shares, reflecting moderate confidence from institutional stakeholders. Public shareholding has also seen a decline, now at 38.16%, which may raise flags about retail investor sentiment towards the stock. The number of shareholders has decreased to 47,954, suggesting a potential consolidation of investor interest. The relatively high DII stake indicates a level of confidence in the company’s prospects, but the declining public interest could be a point of concern that warrants attention.
Outlook, Risks, and Final Insight
Looking ahead, Amrutanjan’s performance will largely depend on its ability to stabilize revenue growth and enhance profitability margins. The healthcare sector is poised for growth as consumer awareness increases, yet Amrutanjan faces challenges such as fluctuating sales and operational efficiency. Risks include potential supply chain disruptions and competitive pressures from both established and emerging players in the pharmaceuticals market. Additionally, the high valuation metrics may limit the stock’s upside potential if the company fails to meet growth expectations. Investors should closely monitor Amrutanjan’s quarterly performances and strategic initiatives aimed at expanding its product portfolio and market reach. While the company has a strong balance sheet and low debt levels, the inconsistent profitability and declining public interest could pose challenges. Overall, retail investors should balance their optimism with caution, given the mixed signals from the financials and market sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 147 Cr. | 116 | 235/84.3 | 32.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,405 Cr. | 405 | 479/192 | 91.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.7 Cr. | 48.2 | 89.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.3 Cr. | 33.0 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,165.85 Cr | 1,151.18 | 52.66 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70.95 | 110.72 | 97.65 | 100.32 | 77.86 | 99.31 | 116.99 | 127.06 | 83.74 | 109.92 | 122.75 | 135.41 | 94.05 |
| Expenses | 67.62 | 94.79 | 85.49 | 87.34 | 70.71 | 92.47 | 95.42 | 110.82 | 80.19 | 96.32 | 99.40 | 117.71 | 85.61 |
| Operating Profit | 3.33 | 15.93 | 12.16 | 12.98 | 7.15 | 6.84 | 21.57 | 16.24 | 3.55 | 13.60 | 23.35 | 17.70 | 8.44 |
| OPM % | 4.69% | 14.39% | 12.45% | 12.94% | 9.18% | 6.89% | 18.44% | 12.78% | 4.24% | 12.37% | 19.02% | 13.07% | 8.97% |
| Other Income | 3.01 | 3.03 | 3.68 | 4.82 | 3.69 | 3.95 | 3.76 | 4.95 | 4.45 | 4.05 | 4.36 | 4.82 | 4.43 |
| Interest | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.04 | 0.05 |
| Depreciation | 1.07 | 1.52 | 1.31 | 1.31 | 1.39 | 1.55 | 1.58 | 1.53 | 1.59 | 1.65 | 1.66 | 1.62 | 1.53 |
| Profit before tax | 5.25 | 17.42 | 14.51 | 16.47 | 9.43 | 9.21 | 23.70 | 19.61 | 6.35 | 15.94 | 25.99 | 20.86 | 11.29 |
| Tax % | 30.29% | 26.75% | 26.12% | 22.95% | 25.56% | 25.62% | 26.41% | 30.34% | 27.24% | 25.97% | 25.93% | 27.23% | 26.40% |
| Net Profit | 3.66 | 12.77 | 10.71 | 12.70 | 7.01 | 6.85 | 17.45 | 13.66 | 4.62 | 11.80 | 19.25 | 15.18 | 8.31 |
| EPS in Rs | 1.25 | 4.37 | 3.66 | 4.34 | 2.40 | 2.37 | 6.04 | 4.72 | 1.60 | 4.08 | 6.66 | 5.25 | 2.87 |
Last Updated: August 20, 2025, 1:50 pm
Below is a detailed analysis of the quarterly data for Amrutanjan Health Care Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 94.05 Cr.. The value appears to be declining and may need further review. It has decreased from 135.41 Cr. (Mar 2025) to 94.05 Cr., marking a decrease of 41.36 Cr..
- For Expenses, as of Jun 2025, the value is 85.61 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 117.71 Cr. (Mar 2025) to 85.61 Cr., marking a decrease of 32.10 Cr..
- For Operating Profit, as of Jun 2025, the value is 8.44 Cr.. The value appears to be declining and may need further review. It has decreased from 17.70 Cr. (Mar 2025) to 8.44 Cr., marking a decrease of 9.26 Cr..
- For OPM %, as of Jun 2025, the value is 8.97%. The value appears to be declining and may need further review. It has decreased from 13.07% (Mar 2025) to 8.97%, marking a decrease of 4.10%.
- For Other Income, as of Jun 2025, the value is 4.43 Cr.. The value appears to be declining and may need further review. It has decreased from 4.82 Cr. (Mar 2025) to 4.43 Cr., marking a decrease of 0.39 Cr..
- For Interest, as of Jun 2025, the value is 0.05 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.04 Cr. (Mar 2025) to 0.05 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Jun 2025, the value is 1.53 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.62 Cr. (Mar 2025) to 1.53 Cr., marking a decrease of 0.09 Cr..
- For Profit before tax, as of Jun 2025, the value is 11.29 Cr.. The value appears to be declining and may need further review. It has decreased from 20.86 Cr. (Mar 2025) to 11.29 Cr., marking a decrease of 9.57 Cr..
- For Tax %, as of Jun 2025, the value is 26.40%. The value appears to be improving (decreasing) as expected. It has decreased from 27.23% (Mar 2025) to 26.40%, marking a decrease of 0.83%.
- For Net Profit, as of Jun 2025, the value is 8.31 Cr.. The value appears to be declining and may need further review. It has decreased from 15.18 Cr. (Mar 2025) to 8.31 Cr., marking a decrease of 6.87 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.87. The value appears to be declining and may need further review. It has decreased from 5.25 (Mar 2025) to 2.87, marking a decrease of 2.38.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 131 | 154 | 174 | 207 | 220 | 253 | 261 | 333 | 406 | 380 | 421 | 452 | 470 |
| Expenses | 108 | 130 | 143 | 178 | 192 | 222 | 231 | 258 | 326 | 335 | 369 | 394 | 404 |
| Operating Profit | 23 | 25 | 32 | 29 | 28 | 31 | 31 | 75 | 80 | 45 | 52 | 58 | 66 |
| OPM % | 18% | 16% | 18% | 14% | 13% | 12% | 12% | 22% | 20% | 12% | 12% | 13% | 14% |
| Other Income | 3 | 5 | 6 | 7 | 8 | 7 | 8 | 11 | 15 | 15 | 16 | 18 | 18 |
| Interest | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 2 | 3 | 2 | 3 | 3 | 4 | 4 | 4 | 5 | 6 | 7 | 6 |
| Profit before tax | 21 | 26 | 35 | 34 | 33 | 35 | 34 | 82 | 91 | 54 | 62 | 69 | 77 |
| Tax % | 32% | 35% | 35% | 35% | 39% | 29% | 27% | 25% | 26% | 26% | 27% | 26% | |
| Net Profit | 15 | 17 | 22 | 22 | 20 | 25 | 25 | 61 | 67 | 40 | 45 | 51 | 57 |
| EPS in Rs | 4.97 | 5.86 | 7.68 | 7.47 | 6.84 | 8.39 | 8.58 | 20.93 | 22.99 | 13.63 | 15.55 | 17.58 | 19.61 |
| Dividend Payout % | 32% | 30% | 25% | 26% | 22% | 26% | 24% | 20% | 20% | 34% | 30% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 13.33% | 29.41% | 0.00% | -9.09% | 25.00% | 0.00% | 144.00% | 9.84% | -40.30% | 12.50% | 13.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 16.08% | -29.41% | -9.09% | 34.09% | -25.00% | 144.00% | -134.16% | -50.13% | 52.80% | 0.83% |
Amrutanjan Health Care Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 12% |
| 3 Years: | 4% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 15% |
| 3 Years: | -9% |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | -1% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 20% |
| 3 Years: | 15% |
| Last Year: | 17% |
Last Updated: September 4, 2025, 11:10 pm
Balance Sheet
Last Updated: December 10, 2025, 2:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 94 | 102 | 118 | 113 | 126 | 143 | 156 | 213 | 262 | 288 | 286 | 324 | 339 |
| Borrowings | 6 | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 1 | 1 | 2 | 2 | 2 |
| Other Liabilities | 22 | 25 | 28 | 34 | 38 | 42 | 44 | 57 | 84 | 70 | 77 | 93 | 88 |
| Total Liabilities | 124 | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 | 432 |
| Fixed Assets | 15 | 13 | 22 | 27 | 28 | 26 | 26 | 23 | 28 | 49 | 50 | 49 | 49 |
| CWIP | 1 | 4 | 1 | 1 | 0 | 0 | 0 | 2 | 17 | 1 | 2 | 16 | 26 |
| Investments | 14 | 14 | 10 | 10 | 8 | 18 | 18 | 18 | 13 | 5 | 0 | 0 | 0 |
| Other Assets | 95 | 100 | 116 | 115 | 131 | 144 | 161 | 232 | 291 | 307 | 315 | 356 | 357 |
| Total Assets | 124 | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 | 432 |
Below is a detailed analysis of the balance sheet data for Amrutanjan Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Reserves, as of Sep 2025, the value is 339.00 Cr.. The value appears strong and on an upward trend. It has increased from 324.00 Cr. (Mar 2025) to 339.00 Cr., marking an increase of 15.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 88.00 Cr.. The value appears to be improving (decreasing). It has decreased from 93.00 Cr. (Mar 2025) to 88.00 Cr., marking a decrease of 5.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 432.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 421.00 Cr. (Mar 2025) to 432.00 Cr., marking an increase of 11.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 49.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 49.00 Cr..
- For CWIP, as of Sep 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 10.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 357.00 Cr.. The value appears strong and on an upward trend. It has increased from 356.00 Cr. (Mar 2025) to 357.00 Cr., marking an increase of 1.00 Cr..
- For Total Assets, as of Sep 2025, the value is 432.00 Cr.. The value appears strong and on an upward trend. It has increased from 421.00 Cr. (Mar 2025) to 432.00 Cr., marking an increase of 11.00 Cr..
Notably, the Reserves (339.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 17.00 | 25.00 | 32.00 | 27.00 | 28.00 | 31.00 | 29.00 | 74.00 | 79.00 | 44.00 | 50.00 | 56.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 62 | 55 | 51 | 46 | 47 | 37 | 19 | 34 | 32 | 42 | 45 |
| Inventory Days | 45 | 44 | 44 | 44 | 40 | 45 | 74 | 45 | 53 | 58 | 50 | 45 |
| Days Payable | 44 | 46 | 51 | 110 | 102 | 92 | 98 | 106 | 122 | 95 | 96 | 113 |
| Cash Conversion Cycle | 67 | 61 | 48 | -15 | -16 | 0 | 13 | -41 | -35 | -6 | -5 | -23 |
| Working Capital Days | 39 | 42 | 45 | 76 | 26 | 30 | 70 | 28 | 92 | 117 | 173 | 99 |
| ROCE % | 24% | 26% | 29% | 28% | 25% | 25% | 23% | 44% | 38% | 19% | 21% | 22% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| DSP Small Cap Fund | 1,466,269 | 0.59 | 99.85 | 1,466,269 | 2025-04-22 15:57:00 | 0% |
| ICICI Prudential FMCG Fund | 713,715 | 2.48 | 48.6 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 14.47 | 14.08 | 10.31 | 8.51 | 6.92 |
| Diluted EPS (Rs.) | 14.47 | 14.08 | 10.31 | 8.51 | 6.92 |
| Cash EPS (Rs.) | 16.43 | 16.37 | 12.51 | 10.98 | 9.47 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 86.22 | 74.40 | 64.97 | 61.06 | 56.29 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 86.22 | 74.40 | 64.97 | 61.06 | 56.29 |
| Revenue From Operations / Share (Rs.) | 153.25 | 127.77 | 113.97 | 96.97 | 94.18 |
| PBDIT / Share (Rs.) | 23.16 | 24.95 | 19.32 | 16.93 | 14.83 |
| PBIT / Share (Rs.) | 21.20 | 22.66 | 17.13 | 14.47 | 12.28 |
| PBT / Share (Rs.) | 22.75 | 22.36 | 16.64 | 13.26 | 10.59 |
| Net Profit / Share (Rs.) | 14.47 | 14.08 | 10.31 | 8.51 | 6.92 |
| NP After MI And SOA / Share (Rs.) | 14.47 | 14.08 | 10.31 | 8.51 | 6.92 |
| PBDIT Margin (%) | 15.11 | 19.52 | 16.95 | 17.46 | 15.75 |
| PBIT Margin (%) | 13.83 | 17.73 | 15.02 | 14.92 | 13.04 |
| PBT Margin (%) | 14.84 | 17.50 | 14.60 | 13.67 | 11.24 |
| Net Profit Margin (%) | 9.43 | 11.01 | 9.04 | 8.78 | 7.34 |
| NP After MI And SOA Margin (%) | 9.43 | 11.01 | 9.04 | 8.78 | 7.34 |
| Return on Networth / Equity (%) | 16.77 | 18.92 | 15.87 | 13.94 | 12.29 |
| Return on Capital Employeed (%) | 23.87 | 29.45 | 25.52 | 22.73 | 20.83 |
| Return On Assets (%) | 13.07 | 14.65 | 12.16 | 10.34 | 8.14 |
| Total Debt / Equity (X) | 0.01 | 0.02 | 0.02 | 0.08 | 0.18 |
| Asset Turnover Ratio (%) | 1.48 | 1.35 | 1.30 | 1.12 | 1.00 |
| Current Ratio (X) | 3.46 | 3.59 | 3.20 | 2.87 | 1.67 |
| Quick Ratio (X) | 3.15 | 3.27 | 2.87 | 2.55 | 1.40 |
| Inventory Turnover Ratio (X) | 7.67 | 7.09 | 6.93 | 6.06 | 5.44 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 27.34 | 33.93 | 37.58 | 43.33 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 23.52 | 27.97 | 29.14 | 31.67 |
| Earning Retention Ratio (%) | 0.00 | 72.66 | 66.07 | 62.42 | 56.67 |
| Cash Earning Retention Ratio (%) | 0.00 | 76.48 | 72.03 | 70.86 | 68.33 |
| Interest Coverage Ratio (X) | 78.72 | 83.47 | 39.72 | 14.01 | 8.75 |
| Interest Coverage Ratio (Post Tax) (X) | 43.91 | 48.10 | 22.20 | 8.05 | 5.08 |
| Enterprise Value (Cr.) | 817.64 | 564.15 | 663.81 | 156.21 | 169.76 |
| EV / Net Operating Revenue (X) | 3.65 | 3.02 | 3.99 | 1.10 | 1.23 |
| EV / EBITDA (X) | 24.16 | 15.47 | 23.51 | 6.31 | 7.83 |
| MarketCap / Net Operating Revenue (X) | 3.85 | 3.27 | 4.20 | 1.29 | 1.23 |
| Retention Ratios (%) | 0.00 | 72.65 | 66.06 | 62.41 | 56.66 |
| Price / BV (X) | 6.85 | 5.61 | 7.36 | 2.06 | 2.06 |
| Price / Net Operating Revenue (X) | 3.85 | 3.27 | 4.20 | 1.29 | 1.23 |
| EarningsYield | 0.02 | 0.03 | 0.02 | 0.06 | 0.05 |
After reviewing the key financial ratios for Amrutanjan Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 17, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 16) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
- For Diluted EPS (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
- For Cash EPS (Rs.), as of Mar 17, the value is 16.43. This value is within the healthy range. It has increased from 16.37 (Mar 16) to 16.43, marking an increase of 0.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 86.22. It has increased from 74.40 (Mar 16) to 86.22, marking an increase of 11.82.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 86.22. It has increased from 74.40 (Mar 16) to 86.22, marking an increase of 11.82.
- For Revenue From Operations / Share (Rs.), as of Mar 17, the value is 153.25. It has increased from 127.77 (Mar 16) to 153.25, marking an increase of 25.48.
- For PBDIT / Share (Rs.), as of Mar 17, the value is 23.16. This value is within the healthy range. It has decreased from 24.95 (Mar 16) to 23.16, marking a decrease of 1.79.
- For PBIT / Share (Rs.), as of Mar 17, the value is 21.20. This value is within the healthy range. It has decreased from 22.66 (Mar 16) to 21.20, marking a decrease of 1.46.
- For PBT / Share (Rs.), as of Mar 17, the value is 22.75. This value is within the healthy range. It has increased from 22.36 (Mar 16) to 22.75, marking an increase of 0.39.
- For Net Profit / Share (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
- For NP After MI And SOA / Share (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
- For PBDIT Margin (%), as of Mar 17, the value is 15.11. This value is within the healthy range. It has decreased from 19.52 (Mar 16) to 15.11, marking a decrease of 4.41.
- For PBIT Margin (%), as of Mar 17, the value is 13.83. This value is within the healthy range. It has decreased from 17.73 (Mar 16) to 13.83, marking a decrease of 3.90.
- For PBT Margin (%), as of Mar 17, the value is 14.84. This value is within the healthy range. It has decreased from 17.50 (Mar 16) to 14.84, marking a decrease of 2.66.
- For Net Profit Margin (%), as of Mar 17, the value is 9.43. This value is within the healthy range. It has decreased from 11.01 (Mar 16) to 9.43, marking a decrease of 1.58.
- For NP After MI And SOA Margin (%), as of Mar 17, the value is 9.43. This value is within the healthy range. It has decreased from 11.01 (Mar 16) to 9.43, marking a decrease of 1.58.
- For Return on Networth / Equity (%), as of Mar 17, the value is 16.77. This value is within the healthy range. It has decreased from 18.92 (Mar 16) to 16.77, marking a decrease of 2.15.
- For Return on Capital Employeed (%), as of Mar 17, the value is 23.87. This value is within the healthy range. It has decreased from 29.45 (Mar 16) to 23.87, marking a decrease of 5.58.
- For Return On Assets (%), as of Mar 17, the value is 13.07. This value is within the healthy range. It has decreased from 14.65 (Mar 16) to 13.07, marking a decrease of 1.58.
- For Total Debt / Equity (X), as of Mar 17, the value is 0.01. This value is within the healthy range. It has decreased from 0.02 (Mar 16) to 0.01, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 17, the value is 1.48. It has increased from 1.35 (Mar 16) to 1.48, marking an increase of 0.13.
- For Current Ratio (X), as of Mar 17, the value is 3.46. This value exceeds the healthy maximum of 3. It has decreased from 3.59 (Mar 16) to 3.46, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 17, the value is 3.15. This value exceeds the healthy maximum of 2. It has decreased from 3.27 (Mar 16) to 3.15, marking a decrease of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 17, the value is 7.67. This value is within the healthy range. It has increased from 7.09 (Mar 16) to 7.67, marking an increase of 0.58.
- For Dividend Payout Ratio (NP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 27.34 (Mar 16) to 0.00, marking a decrease of 27.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 23.52 (Mar 16) to 0.00, marking a decrease of 23.52.
- For Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 72.66 (Mar 16) to 0.00, marking a decrease of 72.66.
- For Cash Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 76.48 (Mar 16) to 0.00, marking a decrease of 76.48.
- For Interest Coverage Ratio (X), as of Mar 17, the value is 78.72. This value is within the healthy range. It has decreased from 83.47 (Mar 16) to 78.72, marking a decrease of 4.75.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 17, the value is 43.91. This value is within the healthy range. It has decreased from 48.10 (Mar 16) to 43.91, marking a decrease of 4.19.
- For Enterprise Value (Cr.), as of Mar 17, the value is 817.64. It has increased from 564.15 (Mar 16) to 817.64, marking an increase of 253.49.
- For EV / Net Operating Revenue (X), as of Mar 17, the value is 3.65. This value exceeds the healthy maximum of 3. It has increased from 3.02 (Mar 16) to 3.65, marking an increase of 0.63.
- For EV / EBITDA (X), as of Mar 17, the value is 24.16. This value exceeds the healthy maximum of 15. It has increased from 15.47 (Mar 16) to 24.16, marking an increase of 8.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 17, the value is 3.85. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 16) to 3.85, marking an increase of 0.58.
- For Retention Ratios (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 72.65 (Mar 16) to 0.00, marking a decrease of 72.65.
- For Price / BV (X), as of Mar 17, the value is 6.85. This value exceeds the healthy maximum of 3. It has increased from 5.61 (Mar 16) to 6.85, marking an increase of 1.24.
- For Price / Net Operating Revenue (X), as of Mar 17, the value is 3.85. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 16) to 3.85, marking an increase of 0.58.
- For EarningsYield, as of Mar 17, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 16) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Amrutanjan Health Care Ltd:
- Net Profit Margin: 9.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.87% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.77% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 43.91
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.15
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.9 (Industry average Stock P/E: 52.66)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.43%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | No.103 (Old No.42-45), Chennai (Madras) Tamil Nadu 600004 | shares@amrutanjan.com http://www.amrutanjan.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Sambhu Prasad | Chairman & Managing Director |
| Mr. G Raghavan | Non Executive Director |
| Ms. Ramaa Prabhakar Arikirevula | Non Executive Director |
| Ms. Meenalochani Raghunathan | Ind. Non-Executive Director |
| Mr. Raja Venkataraman | Ind. Non-Executive Director |
| Mr. S Muralidharan | Ind. Non-Executive Director |
| Mr. V Nagaraj | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Amrutanjan Health Care Ltd?
Amrutanjan Health Care Ltd's intrinsic value (as of 19 December 2025) is 547.19 which is 20.12% lower the current market price of 685.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,980 Cr. market cap, FY2025-2026 high/low of 843/544, reserves of ₹339 Cr, and liabilities of 432 Cr.
What is the Market Cap of Amrutanjan Health Care Ltd?
The Market Cap of Amrutanjan Health Care Ltd is 1,980 Cr..
What is the current Stock Price of Amrutanjan Health Care Ltd as on 19 December 2025?
The current stock price of Amrutanjan Health Care Ltd as on 19 December 2025 is 685.
What is the High / Low of Amrutanjan Health Care Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Amrutanjan Health Care Ltd stocks is 843/544.
What is the Stock P/E of Amrutanjan Health Care Ltd?
The Stock P/E of Amrutanjan Health Care Ltd is 34.9.
What is the Book Value of Amrutanjan Health Care Ltd?
The Book Value of Amrutanjan Health Care Ltd is 118.
What is the Dividend Yield of Amrutanjan Health Care Ltd?
The Dividend Yield of Amrutanjan Health Care Ltd is 0.66 %.
What is the ROCE of Amrutanjan Health Care Ltd?
The ROCE of Amrutanjan Health Care Ltd is 22.4 %.
What is the ROE of Amrutanjan Health Care Ltd?
The ROE of Amrutanjan Health Care Ltd is 16.5 %.
What is the Face Value of Amrutanjan Health Care Ltd?
The Face Value of Amrutanjan Health Care Ltd is 1.00.